Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Lucid Group Inc (LCID) vs 10X Genomics Inc (TXG) Price & Performance

Lucid Group IncTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Lucid Group Inc vs 10X Genomics Inc — how do they compare? Lucid Group Inc trades at $6.7 (market cap $2.64B), while 10X Genomics Inc trades at $57.54 (market cap $7.61B). The key difference: 10X Genomics Inc is far larger — about 2.9× Lucid Group Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals.

LCIDTXG
Market Cap
$2.64B$7.61B
Sector
Consumer CyclicalHealth
52-Week High
$24.77$58.57
52-Week Low
$4.62$11.34
Enterprise Value
$5.54B$7.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Lucid Group Inc

Lucid Group (LCID) trades at $6.61, down 6.11% amid ongoing operational challenges. The stock shows bearish technical signals with negative moving averages and faces fundamental headwinds including consistent quarterly losses, negative profit margins, and substantial cash burn. Recent news highlights an operational reset targeting $1.4 billion in cash improvements and delays to the affordable Cosmos EV launch to 2027.

The outlook remains challenging with deep losses and cash burn overshadowing revenue growth. Analyst consensus is cautious with 67% hold ratings, though the $10.50 price target suggests potential upside. Key risks include execution of turnaround plans, intense EV competition, and funding needs. The stock's direction hinges on successful cost reductions and future product execution.

10X Genomics Inc

TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.

Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Lucid Group Inc

Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.

Read more on LCID

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG